Advertisement

American Association of Endocrine Surgeons Meeting: Presidential Address

  • Thomas J. Fahey III
    Correspondence
    Reprint requests: Thomas J. Fahey, III, MD, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065.
    Affiliations
    Professor and Vice-Chair, Department of Surgery and Director, Endocrine Oncology Program, The New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY
    Search for articles by this author
Published:November 16, 2022DOI:https://doi.org/10.1016/j.surg.2022.09.035
      It has truly been a privilege to be your president over the last year and having the opportunity to help guide my favorite professional organization out of the COVID pandemic has been particularly humbling.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tracey K.J.
        • Beutler B.
        • Lowry S.F.
        • et al.
        Shock and tissue injury induced by recombinant human cachectin.
        Science. 1986; 234: 470-474
        • Kim N.W.
        • Piatyszek M.A.
        • Prowse K.R.
        • et al.
        Specific association of human telomerase activity with immortal cells and cancer.
        Science. 1994; 266: 2011-2015
        • Yashima K.
        • Vuitch F.
        • Gazdar A.F.
        • Fahey III, T.J.
        Telomerase activity in benign and malignant thyroid diseases.
        Surgery. 1997; 122: 1141-1146
        • Saji M.
        • Westra W.H.
        • Chen H.
        • et al.
        Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid.
        Surgery. 1997; 122: 1137-1340
        • Barden C.B.
        • Shister K.W.
        • Zhu B.
        • et al.
        Classification of follicular thyroid tumors by molecular signature: Results of gene profiling.
        Clin Cancer Res. 2003; 9: 1792-1800
        • Lubitz C.
        • Gallagher L.
        • Finley D.
        • Zhu B.
        • Fahey III, T.J.
        Molecular analysis of minimally invasive follicular carcinomas by gene profiling.
        Surgery. 2005; 138: 1042-1048
        • Finley D.
        • Arora N.
        • Zhu B.
        • Gallagher L.
        • Fahey III, T.J.
        Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
        J Clin Endo Metab. 2004; 89: 3214-3223
        • Buitrago D.
        • Keutgen X.M.
        • Crowley M.
        • et al.
        Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
        Ann Surg Oncol. 2012; 19: 973-980
        • Min I.M.
        • Shevlin E.
        • Vedvyas Y.
        • et al.
        CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors.
        Clin Cancer Res. 2017; 23: 7569-7583
        • Dardik R.B.
        • Dardik M.
        • Westra W.
        • Montz F.J.
        Malignant struma ovarii: Two case reports and a review of the literature.
        Gynecol Oncol. 1999; 73: 447-451
        • Marti J.L.
        • Clark V.E.
        • Harper H.
        • Chhieng D.C.
        • Sosa J.A.
        • Roman S.A.
        Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: A series of 4 patients and a review of 53 reported cases.
        Thyroid. 2012; 22: 400-406
        • Egan C.
        • Stefanova D.
        • Thiesmeyer J.W.
        • et al.
        Proposed risk stratification and patterns of radioactive iodine therapy in malignant struma ovarii.
        Thyroid. 2022 Sep; 32: 1101-1108